Reserverlogix (RVX.CN) : Announces Mechanism of Action for RVX-208
Monday, April 23, 2012 at 8:54AM
DDE Editor in Specialty Pharma, rvx
- RVX.CN announced that RVX-208 increases apolipoprotein A-I (ApoA-I) production and that its data shows RVX-208 to be an inhibitor of the Bromodomain and Extraterminal Domain (BET) proteins.
- RVX-208 acts on BET proteins, including BRD4, a member of the BET-protein family, leading to increased transcription of the ApoA-I gene followed by production of more ApoA-I protein.
- Clinical benefits of RVX-208 are currently being explored in two concurrent Phase 2B clinical trials (SUSTAIN and ASSURE), led by Cleveland Clinic.
- As previously announced, Conference Call and Webcast today at 11ET: 800.319.4610 or 604.638.5340
Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).
See website for complete article licensing information.